Cholesteryl butyrate solid lipid nanoparticles as a butyric acid pro-drug:: effects on cell proliferation, cell-cycle distribution and c-myc expression in human leukemic cells

被引:21
作者
Serpe, L
Laurora, S
Pizzimenti, S
Ugazio, E
Ponti, R
Canaparo, R
Briatore, F
Barrera, G
Gasco, MR
Bernengo, MG
Eandi, M
Zara, GP
机构
[1] Univ Turin, Dept Anat Pharmacol & Forens Med, I-10125 Turin, Italy
[2] Univ Turin, Dept Expt Med & Oncol, I-10125 Turin, Italy
[3] Univ Turin, Dept Pharmaceut Sci & Technol, I-10125 Turin, Italy
[4] Univ Turin, Dept Med & Surg Specialities, I-10125 Turin, Italy
关键词
cell cycle; cholesteryl butyrate; c-myc oncogene; sodium butyrate; solid lipid nanoparticles;
D O I
10.1097/01.cad.0000127329.83568.15
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cholesteryl butyrate solid lipid nanoparticles (chol-but SLN) have been proposed as a pro-drug to deliver butyric acid. We compared the effects on cell growth, cell-cycle distribution and c-myc expression of chol-but SLN and sodium butyrate (Na-but) in the human leukemic cell lines Jurkat, U937 and HL-60. In all the cell lines 0.5 and 1.0 mM chol-but SLN provoked a complete block of cell growth. Cell-cycle analysis demonstrated in Jurkat cells that 0.25 mM chol-but SLN caused a pronounced increase of G(2)/M cells and a decrease of G(0)/G(1) cells, whereas in U937 and HL-60 cells chol-but SLN led to a dose-dependent increase of G(0)/G(1) cells, with a decrease of G(2)/M cells. In Jurkat and HL-60 cells 0.5 mM chol-but SLN induced a significant increase of sub-G(0)/G(1) apoptotic cells. Cell growth and cell-cycle distribution were unaffected by the same concentrations of Na-but A concentration of 0.25 mM chol-but SLN was able to cause a rapid and transient down-regulation of c-myc expression in all the cell lines, whereas 1 mM Na-but caused a slight reduction of c-myc expression only in U937 cells. The results show how chol-but SLN affects the proliferation pattern of both myeloid and lymphoid cells to an extent greater than the natural butyrate. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:525 / 536
页数:12
相关论文
共 42 条
[21]  
Moghimi SM, 2001, PHARMACOL REV, V53, P283
[22]  
NOVOGRODSKY A, 1983, CANCER-AM CANCER SOC, V51, P9, DOI 10.1002/1097-0142(19830101)51:1<9::AID-CNCR2820510104>3.0.CO
[23]  
2-4
[24]  
Pellizzaro C, 1999, ANTICANCER RES, V19, P3921
[25]   ISOBUTYRAMIDE, AN ORALLY BIOAVAILABLE BUTYRATE ANALOG, STIMULATES FETAL GLOBIN GENE-EXPRESSION IN-VITRO AND IN-VIVO [J].
PERRINE, SP ;
DOVER, GH ;
DAFTARI, P ;
WALSH, CT ;
JIN, YX ;
MAYS, A ;
FALLER, DV .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 88 (03) :555-561
[26]   Inhibition of D1, D2, and a cyclin expression in HL-60 cells by the lipid peroxydation product 4-hydroxynonenal [J].
Pizzimenti, S ;
Barrera, G ;
Dianzani, MU ;
Brüsselbach, S .
FREE RADICAL BIOLOGY AND MEDICINE, 1999, 26 (11-12) :1578-1586
[27]  
POUILLART P, 1991, INT J CANCER, V49, P889
[28]   RAPID ALTERATION OF C-MYC AND C-JUN EXPRESSION IN LEUKEMIC-CELLS INDUCED TO DIFFERENTIATE BY A BUTYRIC-ACID PRODRUG [J].
RABIZADEH, E ;
SHAKLAI, M ;
NUDELMAN, A ;
EISENBACH, L ;
REPHAELI, A .
FEBS LETTERS, 1993, 328 (03) :225-229
[29]   DERIVATIVES OF BUTYRIC-ACID AS POTENTIAL ANTINEOPLASTIC AGENTS [J].
REPHAELI, A ;
RABIZADEH, E ;
AVIRAM, A ;
SHAKLAI, M ;
RUSE, M ;
NUDELMAN, A .
INTERNATIONAL JOURNAL OF CANCER, 1991, 49 (01) :66-72
[30]   In vitro effects of cholesteryl butyrate solid lipid nanospheres as a butyric acid pro-drug on melanoma cells:: Evaluation of antiproliferative activity and apoptosis induction [J].
Salomone, B ;
Ponti, R ;
Gasco, MR ;
Ugazio, E ;
Quaglino, P ;
Osella-Abate, S ;
Bernengo, MG .
CLINICAL & EXPERIMENTAL METASTASIS, 2001, 18 (08) :663-673